login
register
Home
Getting Started
ChartMill Overview
Growth Traders
Technical Swing Traders
Long Term Investors
Tools
Stock Screener
Stock Charts
Full Screen Stock Charts
Market Monitor
Sectors
Earnings
Analyzer
Insider Trading
Up- and Downgrades
Stock Market
Top Gainers and Losers
New 52 Week High and Low
Gap Up and Gap Down
Most Active
Premarket Movers
After-Hours Movers
Earnings Calendar
USA Market Overview
Canada Market Overview
Europe Market Overview
Trading Ideas
News
Blog
Documentation
Documentation Center
Videos
Indicators
Properties
Screener Market data
Popular Articles
Bull Flags
Relative Strength
Pocket Pivots
Support and Resistance
RSI Indicator
MACD Indicator
Piotroski F-score
Squeeze Plays
Weinstein
Technical Breakout Setups
Trading Tips
Premarket Movers
Gap Up Stocks
Best Dividend Stocks
Bullish Engulfing Pattern
Ascending Triangle Pattern
Swing Trading
All articles ...
Subscriptions
Swing Trading Course
Account
Disclaimer
Affiliate
Contact
Privacy
QUOIN PHARMACEUTICALS LT-ADR (QNRX) Stock News
USA
- NASDAQ:QNRX -
US74907L4095
-
ADR
9.01
USD
+0.44 (+5.13%)
Last: 11/7/2025, 8:10:47 PM
Overview
Stock Chart
Technical Analysis
Fundamental Analysis
Analyst Ratings
Earnings Estimates
Financials
Ownership
News
QNRX Latest News, Press Relases and Analysis
All
Press Releases
3 days ago - By: Quoin Pharmaceuticals, Inc.
Quoin Pharmaceuticals Announces Corporate Update and Third Quarter 2025 Financial Results
3 days ago - By: Benzinga
- Mentions:
STVN
PODD
AMRK
SOLV
...
Earnings Scheduled For November 6, 2025
10 days ago - By: Quoin Pharmaceuticals, Inc.
Quoin Pharmaceuticals to Provide Corporate Update and Announce Third Quarter 2025 Financial Results on Thursday, November 6, 2025
19 days ago - By: Quoin Pharmaceuticals, Inc.
Quoin Pharmaceuticals Announces U.S. FDA Grants Orphan Drug Designation for QRX003 in Netherton Syndrome
a month ago - By: Benzinga
- Mentions:
PDEX
NDRA
SRRK
IMAB
...
12 Health Care Stocks Moving In Monday's Intraday Session
a month ago - By: Stocktwits
QNRX Stock Soars 300% After $104.5M Financing Through Private Placement
a month ago - By: Quoin Pharmaceuticals, Inc.
Quoin Pharmaceuticals Announces Private Placement Financing of Up to $104.5 Million
2 months ago - By: Quoin Pharmaceuticals, Inc.
Quoin Pharmaceuticals Releases Fifth NETHERTON NOW Video Featuring Writers and Influencers Allie and Kaleigh Fasanella, Twin Sisters Living with Netherton Syndrome
3 months ago - By: Quoin Pharmaceuticals, Inc.
Quoin Pharmaceuticals’ NETHERTON NOW Campaign Surpasses One Million Video Views, Amplifying Global Awareness of Netherton Syndrome
3 months ago - By: Quoin Pharmaceuticals, Inc.
Quoin Pharmaceuticals Appoints New Chief Financial Officer to Support Commercialization Strategy
3 months ago - By: Quoin Pharmaceuticals, Inc.
Quoin Pharmaceuticals Releases Fourth Episode in NETHERTON NOW Video Series Featuring International Patient Advocate Mandy Aldwin-Easton
3 months ago - By: The Motley Fool
Quoin (QNRX) Q2 Loss Beats Estimates
3 months ago - By: Quoin Pharmaceuticals, Inc.
Quoin Pharmaceuticals Announces Second Quarter 2025 Financial Results and Corporate Update
3 months ago - By: Quoin Pharmaceuticals, Inc.
Quoin Pharmaceuticals to Announce Second Quarter 2025 Financial Results on Thursday, August 7, 2025
3 months ago - By: Quoin Pharmaceuticals, Inc.
Quoin Pharmaceuticals Provides Product Portfolio Update
5 months ago - By: Quoin Pharmaceuticals, Inc.
Quoin Pharmaceuticals Releases New NETHERTON NOW Video Featuring Professor Jemima Mellerio, International Expert in Genetic Skin Diseases
6 months ago - By: Quoin Pharmaceuticals, Inc.
Quoin Pharmaceuticals Announces FDA Clearance to Initiate Second Pivotal Whole Body QRX003 Netherton Syndrome Clinical Study
6 months ago - By: Quoin Pharmaceuticals, Inc.
Quoin Pharmaceuticals Announces European Medicines Agency (EMA) Grants Orphan Drug Designation for QRX003 for the Treatment of Netherton Syndrome
6 months ago - By: Stocktwits
Retail Buzz Intensifies Around Quoin Pharma Stock After Positive Pediatric Skin Study Data
Please enable JavaScript to continue using this application.